In December, MGA CEO Alex Brill participated in a RealClearPolitics event looking at the negative consequences of limiting the business practices of PBMs.
Alex Brill recently joined the GRx+Biosims 2023 conference panel to discuss biosimilars and the keys to success in the pharmacy benefit.
Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings?
On October 3, AEI’s Alex Brill and Kyle Pomerleau hosted a panel of experts to discuss the tax treatment of pass-through businesses and opportunities for reform.
Three policy experts join Richard Rubin of The Wall Street Journal to examine the current iteration of the Build Back Better Act.
Alex Brill was one of the panelists discussing his “commitment to expand biosimilar use in the United States and how physicians and government officials are looking to help.